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Abstract
Understanding the molecular mechanisms behind beta cell dysfunction is essential for the development of effective and specific
approaches for diabetes care and prevention. Physiological human beta cell models are needed for this work. We review the
possibilities and limitations of currently available human beta cell models and how they can be dramatically enhanced using
genome-editing technologies. In addition to the gold standard, primary isolated islets, other models now include immortalised
human beta cell lines and pluripotent stem cell-derived islet-like cells. The scarcity of human primary islet samples limits their
use, but valuable gene expression and functional data from large collections of human islets have been made available to the
scientific community. The possibilities for studying beta cell physiology using immortalised human beta cell lines and stem cell-
derived islets are rapidly evolving. However, the functional immaturity of these cells is still a significant limitation. CRISPR-
Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9) has enabled precise engineer-
ing of specific genetic variants, targeted transcriptional modulation and genome-wide genetic screening. These approaches can
now be exploited to gain understanding of the mechanisms behind coding and non-coding diabetes-associated genetic variants,
allowing more precise evaluation of their contribution to diabetes pathogenesis. Despite all the progress, genome editing in
primary pancreatic islets remains difficult to achieve, an important limitation requiring further technological development.
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Introduction
Failing beta cell function is a major culprit in all forms of
diabetes. In type 1 diabetes this results from an interaction
between genetic predisposition and environmental factors,
culminating in an immune-mediated loss of beta cells. In
monogenic diabetes, insulin secretion is deficient entirely
based on mutations in genes that are important for beta cell
function. Type 2 diabetes is considered to result from a colli-
sion between genetic predisposition and an affluent environ-
ment, which means that type 2 diabetes develops when people
no longer can increase their insulin secretion to meet the in-
creased demands imposed by obesity and insulin resistance.
Not surprisingly, most of the 403 genetic variants identified in
genome-wide association studies (GWAS) to be associated
with type 2 diabetes [1] have been shown to influence beta
cell function. A problem with these studies is that they have
considered type 2 diabetes as a relatively homogenous dis-
ease. We have recently shown that this is not the case. By
measuring a few pathogenically relevant variables, we could
break down type 2 diabetes into five subgroups with quite
different characteristics and disease progression [2].
Variants in several genes show strong association with type
2 diabetes risk, including those in TCF7L2, SLC30A8 and
MTNR1B [1]. Although the genetic risk of type 1 diabetes is
most strongly associated with the HLA genes, more than 50
additional genes or loci have been associated with the disease,
most being expressed in the pancreatic beta cells [3].
However, it is not easy to infer causality from a common
genetic variant associated with either type 1 or type 2 diabetes.
Therefore, functional studies using genetically defined cells in
appropriate models are required. Possibilities for studying hu-
man beta cell function in vivo are limited. In order to under-
stand the pathogenic role of diabetes-associated genetic vari-
ants, experimental beta cell models are needed. Rodent
models, particularly transgenic mice, have provided a lot of
valuable information but they have limitations due to obvious
genetic and physiological species differences. Essentially,
there are three possible ways to study human beta cells direct-
ly: (1) primary islets isolated from the pancreas of organ do-
nors; (2) clonal human beta cell lines and (3) islet-like cells
differentiated from human pluripotent stem cells (hPSCs),
comprising either human embryonic stem cells (hESCs) or
human induced pluripotent stem cells (hiPSCs) (see Text box).
Primary human islets
Human pancreatic islets obtained from organ donor
pancreases or from pancreatic surgery are very informative,
since they are obtained while the blood flow is still intact,
thereby retaining functionality of the cells. Comprehensive
transcriptomic profiling of such islets, together with GWAS,
has facilitated extensive analysis of expression [4] and effects
of genetic variation on gene expression (i.e. expression quan-
titative traits [eQTLs], splicing [splice QTLS], allelic
Source Benefits Limitations
Primary islets The gold standard Poor availability
High variability
Difficult to maintain
Limited possibilities for genetic
manipulation
Human beta cell Expandability Transformed aneuploid cells
lines Glucose-stimulated insulin secretion Limited possibilities for genome editing
Transcriptomically close to primary beta 
cells
Pluripotent stem Expandability Immaturity
cell-derived islets Can be produced from patients’ cells Variability between stem cell lines
Can be used to study islet development Limited functional life span in vitro
Efficient genome editing
Can be transplanted to generate 
humanised mice
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imbalance [5], cis-regulatory networks [6, 7] and non-coding
RNAs [8]) using collections of isolated human islets. This has
enabled the discovery of numerous genes with a potential role
in glucose metabolism and insulin secretion. In order to make
these resources more accessible to the scientific community,
the Islet Gene View was created, providing comprehensive
information on gene expression in relation to diabetes status,
insulin secretion, expression of other pancreatic genes and
related phenotypes of interest [9]. Overlaying expression data
with data on regions of open chromatin (DNase I hypersensi-
tive sites sequencing [DNase-seq], assay for transposase-
accessible chromatin sequencing [ATAC-seq]) [10], histone
modifications (chromatin immunoprecipitation sequencing
[ChIP-seq]) [11] and spatial chromatin organisation data (Hi-
C, Capture-C or 4-C methods) [12] can facilitate a better un-
derstanding of the genomic regulation critical for appropriate
islet function.
Pancreatic islets consist of multiple cell types, each with
distinctive functions. Performing single-cell mRNA sequenc-
ing on different cell types, including alpha, beta, gamma, delta
and epsilon cells from adult and fetal pancreases, can facilitate
the identification of unique cell-specific expression profiles
[13–15] in the hope of distinguishing profiles between type
2 diabetes and non-diabetic donors [16, 17]. Interestingly, key
type 2 diabetes genes reported from previous studies, such as
TCF7L2 and others, were missing in these data, suggesting
that these studies may have been underpowered or that some
of the earlier studies using bulk RNA sequencing may have
been confounded by signals from cells other than endocrine
cells. In addition, these differences are likely to reflect the
technical limitations of single-cell mRNA sequencing tech-
nologies: limited number of cells analysed and a low gene
detection rate.
Different viral vectors have been exploited to perform over-
expression and perturbation experiments in human islets.
Lentiviruses, adenovirus and adeno-associated viruses
(AAVs) carrying cDNA-expressing constructs or short hairpin
RNA (shRNA) have been transduced to human islet cells [7].
However, genome editing using site-directed endonucleases
in primary islets has not previously been reported, possibly
because this approach may be challenging due to a variety of
factors, including poor delivery efficiency to intact islets, the
quiescent nature of the cells or the sensitivity of the cells to
these manipulations. These limitations might be overcome in
the future with use of optimised Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR)CRISPR-
associated protein 9 (Cas9) approaches, such as those tailored
for primary cells (e.g. Guide Swap [18]), the use of Cas9 base
editors [19] or improved delivery methods to intact islets (e.g.
smaller Cas9 delivered using AAVs). An alternative possibil-
ity would be the use of bioengineered human pseudoislets
[20], in which dissociated cells are treated with CRISPR-
Cas9 and then reaggregated.
Human beta cell lines
Human beta cell lines have been a long-sought resource for
diabetes research. Finally, Scharfmann and co-workers
succeeded in generating stable human beta cell lines from
human fetal pancreatic cells using the SV40LT oncogene un-
der the insulin promoter [21]. The first line, EndoC-βH1, has
now been adopted for use in many laboratories and generally
accepted as a stable glucose-responsive human beta cell line,
which has numerous applications, ranging from studies of
insulin secretion to studies of beta cell damage [22]. The line
has obvious advantages, such as the possibility to expand it in
an unlimited manner and its responsiveness to glucose at a
physiological range. Additional EndoC-βH lines 2 and 3 have
been developed in which the oncogene can be removed,
resulting in cell-cycle arrest and increased insulin secretion
in response to glucose. EndoC-βH cells are amenable to dif-
ferent perturbation experiments since they can be transfected
chemically and electroporated with plasmid vectors or small
interfering RNA (siRNA) molecules, or transduced with viral
vectors [22]. However, it is challenging to genetically modify
this cell line at a clonal level, given its slow growth rate and
low clonal efficiency. Furthermore, it should be remembered
that these are transformed aneuploid cells that cannot be taken
as a direct counterpart of the primary beta cell.
hPSC-based models
The third option for achieving human beta cells for experi-
mental studies is based on the differentiation of hPSCs. The
first report describing successful differentiation of hESCs to
pancreatic endocrine cells was published in 2006 byD’Amour
et al [23]. Since then, the stepwise protocols that are needed to
mimic normal pancreatic differentiation have been further
optimised, resulting in methods that lead to the generation of
large numbers of islet-like cell aggregates consisting predom-
inantly of beta cells that are capable of responding to physio-
logical insulin secretagogues [24, 25]. Metabolic maturation
of the cells, measured as robust glucose-stimulated insulin
secretion, is still difficult to achieve in vitro, but the immature
cells do have a remarkable capacity for maturation after im-
plantation into rodents. This enables the generation of
‘humanised’ mouse models, where the implanted human beta
cells are responsible for glycaemic control in the mouse. We
have recently reviewed the possibilities of stem cell strategies
for the modelling of beta cell pathophysiology elsewhere [26].
Organoid technologies have evolved rapidly, enabling the
generation of self-renewing ‘mini-organs’ from both primary
tissue stem cells and pluripotent stem cells [27]. Pancreatic
organoids have also been described, although this technique
remains unproven as a practical solution for the efficient ex-
pansion and differentiation of pancreatic progenitors.
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The use of stem cells to generate human beta cells is an
optimal approach for several reasons (see Text box); a key
advantage is the possibility of using patient-derived iPSCs as
starting material, making it possible to recapitulate functional
features that are specific for an individual’s genotype. The
recapitulation of normal organ development also allows us
to model developmental defects, which is not possible if
end-stage differentiated islets of beta cells are used.
However, because of the high variability between individual
iPSC lines, findings need to be replicated in a large number of
lines derived from different donors and an equally large num-
ber of control individuals [28]. Considering the demanding
differentiation procedures, this is a formidable challenge.
Therefore, genome editing of stem cells is an attractive possi-
bility for reducing the variability between cell lines and focus-
ing on the impact of specific genetic variants (Fig. 1).
Different genome engineering technologies, like zinc finger
nucleases (ZFN) [29] and transcription activator like effector
nucleases (TALEN) [30], have been used successfully on
hPSCs but these have been superseded by CRISPR-Cas9
Fig. 1 The central role of human beta cell models in the functional anal-
ysis of diabetes-associated genotypes. Genetic variants identified in peo-
ple affected with diabetes (via genetic studies) can be interpreted using
integrated functional genomic data (databases, prediction tools, epigenet-
ic data, etc.). Candidate genetic variants require validation in relevant
experimental models. Genome engineering technologies (e.g. gene
knockout, base editing and genetic recombination) facilitate the genetic
manipulation of cellular models to elucidate the role of the candidate
genetic variants. In particular, genome engineering using CRISPR-Cas9
systems (consisting of two parts: a Cas9 endonuclease protein and
gRNAs) have recently opened exciting new avenues for interrogating
the functional impact of diabetes-associated genetic variants. These ge-
nome engineeredmodels might also be utilised as scalable drug-screening
platforms. Understanding the functional impact of diabetes-associated
genetic variants will allow better diagnosis and stratification of diabetes
cases, implementation of more effective interventions for diabetes pre-
vention and more optimal personalised treatment for people affected by
diabetes. KO, knockout; RNAseq, RNA sequencing;WES, whole exome
sequencing; WGS, whole genome sequencing. This figure is available as
a downloadable slide
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technology, which has dramatically improved the possibilities
of genome editing.
Genome editing with CRISPR-Cas9
Genome engineering is based on the use of sequence-specific
endonucleases that introduce DNA double-strand breaks in a
targeted genomic sequence. These targeted cuts may disrupt
that particular sequence, possibly resulting in a gene knock-
out, or stimulate homologous recombination with exogenous
DNA templates (homology-directed repair [HDR]), which
can be exploited to create knockins in order to correct or
introduce point mutations.
The genome editing revolution started in 2013, when the
first CRISPR-Cas9 system was engineered to work in mam-
malian cells [31–33]. The system consists of two parts: a Cas9
endonuclease protein and short RNA molecules, called guide
RNAs (gRNAs). The latter are loaded into the Cas9 protein to
form a ribonucleoprotein complex that seeks and cleaves
DNA sequences complementary to the gRNA sequence.
CRISPR-Cas9 systems have been widely used to disrupt
genes in different cell lines and organisms. CRISPR technol-
ogy and its multiple applications have been thoroughly
reviewed elsewhere [34, 35].
The overall gene disruption efficiency depends on many
factors, including the expression level of Cas9 protein, the
sequence and quality features of the gRNA and the cell-
cycle phase. To generate a reliable gene knockout, gRNAs
should be designed to target all the splice variants of the gene
of interest, including essential functional domains and consid-
ering possible alternative translation start sites. Targeting re-
gions directly downstream of the start codon is also used but
this may result in hypomorphic alleles due to alternative start
sites. Defined genomic regions can also be excised by using
pairs of gRNAs to generate a large deletion. This is particu-
larly useful for studying the importance of non-coding and
regulatory elements [12, 36]. The generation of large deletions
in the genome might have unintended consequences if, for
example, non-annotated regulatory regions are also removed.
For this reason, CRISPR-based genome manipulation experi-
ments should be carefully planned to include appropriate con-
trols and alternative modification approaches (e.g. point mu-
tation introduction, base editing).
The introduction or correction of particular point mutations
using CRISPR-Cas9 is an important application by which to
investigate the role of particular genetic variants. To achieve
this, a Cas9-mediated cut is generated adjacent to the position
of interest while providing a homologous donor template with
the intended nucleotide change, usually in the form of a short
single-stranded DNA oligo, that will recombine by HDR [37].
Another approach is the use of engineered Cas9 versions that
work as base editors, which convert DNA bases (transitions C
to T and A to G) without cleaving the DNA, thereby avoiding
the risks of undesired on- and off-target cut effects [19]. An
interesting advantage of base editing is its high efficiency in
quiescent cells [38], in contrast to the inefficiency of HDR in
non-dividing cells. This could be exploited to manipulate
adult human beta cells, which are largely quiescent.
Exciting novel experimental possibilities have been enabled
by the engineering of catalytically inactive (‘dead’) Cas9 proteins
with transcriptional activator and repressor domains (e.g. repeats
of VP16, Krüppel associated box [KRAB], or epigenetic modu-
lators such as DNA methyltransferase 3α [DNMT3A], p300,
etc.) [39, 40]. These Cas9-based effectors make it possible to
perform hitherto unfeasible targeted transcriptional modulation
and epigenomemodification of endogenous loci. One conceptual
advance has been the development of unbiased CRISPR-Cas9-
based whole-genome genetic screenings, enabling genome-
wide-scale gene knockouts, deletion of regulatory regions and
transcriptional activation or repression [41].
CRISPR-Cas9 tools offer unprecedented experimental ap-
proaches to dissect the mechanisms of beta cell function in
health and disease. They can be used tomodulate transcription
and manipulate the genome in human beta cell lines [12, 36].
They also enable the generation of novel genetically modified
animal models (not only restricted to rodents), allowing com-
parison and the conservation of beta cell function mechanism
across species. CRISPR-Cas9 approaches are also used on
hPSCs to generate gene knockouts [42], correct and introduce
point mutations [43], engineer fluorescent reporter cell lines
and modulate transcription.
Proof of principle
Modelling of monogenic diabetesMonogenic diabetes pre-
sents at a young age due to mutations in a single gene,
leading to impaired function of the pancreatic beta cells.
The exact molecular mechanisms leading to beta cell
failure can be addressed in carefully planned cellular
models. A particular genetic modification (e.g. knock-
out, knockin) can be generated in a well-differentiating,
healthy hPSC line or a candidate mutation can be
corrected in patient-derived hiPSCs. Resulting isogenic
cell line pairs have the same genetic background and
similar differentiation properties, while being discordant
only for the mutation of interest.
Genome editing has been used on hPSCs to knock out
genes critical for pancreatic and beta cell development (e.g.
PDX1, NEUROG3, ARX,GLIS3, NEUROD1), thus reproduc-
ing with human cells previous findings made in transgenic
mouse studies [42, 44, 45]. Furthermore, correction of point
mutations in patient-derived hiPSCs has been exploited to
interrogate the disease mechanism in rare cases of neonatal
diabetes, such as those caused by mutations in STAT3 and
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GATA6 genes [43, 45]. Recently, this strategy was used to
show how diabetogenic mutations in the INS gene lead to
chronic endothelial reticulum stress-associated failure of beta
cell growth [46].
Modelling of polygenic diabetesMore than 400 SNPs associ-
ated with type 2 diabetes and related traits have been identified
thus far. The functional elucidation of these loci has, however,
been largely elusive [1]. For the last 100 years diabetes has
been diagnosed by measuring one metabolite, glucose. This
has of course identified individuals with elevated glucose
levels but provided little information on underlying pathogen-
ic causes. By including six variables (age at diagnosis, BMI,
HbA1c, GAD autoantibodies, C-peptide and glucose [for esti-
mation of insulin secretion, HOMA-B and insulin-sensitivity,
HOMA-IS]) in a clustering analysis of individuals with newly
diagnosed diabetes, we could break down classical type 2
diabetes into five distinct subgroups, with better prediction
of disease progression and outcome [2]. These clusters also
seem to differ in genetic background.
Therefore, gene silencing and functional characterisation
or genome editing of type 2 diabetes risk alleles or deleting
regulatory regions surrounding these variants in human beta
cell models, followed by RNA sequencing (RNAseq) and/
or implementation of spatial chromatin organisation
methods (4C/Hi-C/Capture-C), could facilitate a better un-
derstanding of the functional effects of these variants. In the
human beta cell line EndoC-βH1, the silencing of candidate
genes selected from 75 type 2 diabetes-associated loci re-
vealed 45 genes involved in beta cell function including
ARL15, ZMIZ1, and THADA [47]. Beta cell-specific long
non-coding RNA (lncRNA) transcript knockdown and
coexpression analysis demonstrated the role of lncRNAs
that collaborate with transcription factors to regulate beta
cell-specific transcriptional networks. Further, PLUTO (al-
so known as PLUT), the antisense transcript of the PDX1
gene, modulates the chromatin structure and transcription of
PDX1. Both PDX1 and PLUTO are downregulated in islets
from hyperglycaemic donors [36]. One of the strongest as-
sociation signals for type 2 diabetes is the rs7903146 T
allele SNP in the TCF7L2 gene, and researchers have tried
hard to understand the molecular mechanism behind this
association. Some previous studies have reported increased
chromatin accessibility and episomal enhancer activity for
the T allele SNP and higher TCF7L2 expression was found
in carriers of the TT genotype with type 2 diabetes [48, 49].
Recently, it was shown that CRISPR-mediated deletion of
the region harbouring the type 2 diabetes risk SNP
rs7903146 leads to a decrease in TCF7L2 mRNA levels,
while targeting it with a CRISPR transcriptional activator
had the opposite effect. These findings further indicate that
this region constitutes an enhancer regulating TCF7L2 ex-
pression in human islet cells [12].
The interrogation of type 2 diabetes risk variants could be
performed in an unbiased manner by combining CRISPR-
Cas9-based genome-wide genome and epigenome editing
with single-cell omics to assess the transcriptional and func-
tional outcome of the variants [41]. Genes associated with
type 2 diabetes risk have been knocked out in hPSCs to elu-
cidate their putative role and mechanism predisposing to the
disease (e.g. CDKAL1, KCNQ1) [50]. Further improvements
on the functionality of stem cell-derived beta-like cells will
provide better chances to unravel the functional impact of type
2 diabetes risk variants on beta cell development and physiol-
ogy. First examples of genome-edited hPSC models to eluci-
date the role of specific type 2 diabetes-associated SNPs are
starting to appear, as exemplified by a report where CRISPR-
Cas9-edited hiPSCs and EndoC-βH1 cells were used to in-
vestigate the mechanisms of a protective zinc transporter 8
(Znt8, SLC30A8) variant [51].
Outlook It is easy to predict that the recent technological de-
velopments in human cellular models combined with targeted
genome modification will lead to a boom in functional geno-
mic studies of diabetes during the coming years. The task is
formidable because of the many disease-associated loci in
non-coding DNA regions. Ingenious use of CRISPR-Cas9
and similar techniques will undoubtedly speed up the under-
standing of interplay between type 1 diabetes and type 2 dia-
betes risk-associated genetic variants and their functional role
in predisposing to the disease. These approaches will also be
used in drug screens, enhancing the development of targeted
means for personalised treatment.
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